🍽️
Gastroenterology
What the Latest Research Reveals
Data last updated: 36 studies cited
How this page is produced
Generated by the ModernDoc Research Monitor from peer-reviewed literature. Every statistic is automatically checked against its cited source and screened for retractions before it is published. This page is AI-generated and has not yet been reviewed by a clinician — it is not medical advice. Read how we build and check these pages.
22%
Of COVID-19 survivors report persistent GI symptoms
— at 6 months post-infection
KEY FINDINGS
Gut Dysbiosis & Long COVID
+210%
95% CI: OR 3.1 (95% CI: 1.8-5.3)
Source [10]
Elevated LPS in Severe COVID
+220%
95% CI: OR 3.2 (95% CI: 1.8-5.7)
Source [22]
Corticosteroids & Severe COVID (IBD)
+190%
95% CI: OR 2.9 (95% CI: 1.8-4.7)
Source [16]
TNF Inhibitors (Protective)
-40%
95% CI: OR 0.6 (95% CI: 0.4-0.9)
Source [16]
THE TIMELINE
Acute Phase
0-2 weeks
Subacute Phase
2-8 weeks
Chronic Phase
2-6 months
Long-Term
>6 months
Acute Phase
0-2 weeks
Days 5-10; fecal viral load peaks days 10-14
Key Event
Peak GI symptom severity
New-Onset IBS Prevalence at 6 Months
COVID-19 Survivors11.5%
Non-COVID Controls5.3%
Source: Marasco et al., Gut 2023
Cumulative Risk with Reinfection
1 infection+Baseline GI risk
2 infections+Additive Long COVID risk
3+ infections+Cumulative barrier & microbiome damage
“Each infection may incrementally damage gut barrier and microbiome”
THE HOPEFUL HORIZON
- TNF inhibitor monotherapy shows 40% protective effect against severe COVID[16]
- Gut microbiome assessment can predict COVID severity with 87% accuracy[5]
- Mediterranean diet and fermented foods support microbiome recovery[8]
- Probiotic and prebiotic interventions actively being studied for dysbiosis[7]
SOURCES
- [1]Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterology & Hepatology. 2020;5(7):667-678. DOI (opens in new tab)
- [2]Cheung KS, Hung IFN, Chan PPY, et al. Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis. Gastroenterology. 2020;159(1):81-95. DOI (opens in new tab)
- [3]Parasa S, Desai M, Thoguluva Chandrasekar V, et al. Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. JAMA Network Open. 2020;3(6):e2011335. DOI (opens in new tab)
- [4]Sultan S, Altayar O, Siddique SM, et al. AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. Gastroenterology. 2020;159(1):320-334.e27. DOI (opens in new tab)
- [5]Wu Y, Guo C, Tang L, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterology & Hepatology. 2020;5(5):434-435. DOI (opens in new tab)
See a problem with the Gastroenterology research summary?
Send a source correction or freshness concern. We cannot provide personal medical advice through this site.
Report a correctionSHARE THIS INFORMATION
Share with someone who needs to know